Summary Some oral cancers are preceded by premalignant lesions which include leucoplakia and erythroplakia. At present there are no reliable markers to identify lesions that may progress to malignancy. We have analysed 30 potentially malignant oral lesions for deletions at chromosomal regions that harbour tumoursuppressor genes for oral cancer. A total of 16 of 30 cases (53%) showed loss of heterozygosity (LOH) or allele imbalance at TP53, DCC, 3p2l.3-22.1 or 3pl2.1-13. These genetic alterations were detected in dysplastic lesions but not in histologically normal mucosa and may be early events in the carcinogenic process. A total of 64% of dysplastic lesions that recurred during the study showed LOH or allele imbalance in the initial biopsy and the number of genetic abnormalities increased in the tumours that developed. This type of molecular profiling may help to identify patients with lesions that may recur or acquire additional genetic events and progress to malignancy.
Early treatment of oral cancer offers the best chance of cure. However, patient awareness of this disease is low and as most cases present late treatment is associated with significant physical and psychological morbidity and reduced survival. There is increasing awareness of the potential value of screening for oral cancer and precancer to reduce morbidity and mortality. The most significant oral precancers are leucoplakia (a white patch) and erythroplakia (a red patch) which may show varying degrees of dysplasia. Longitudinal studies have shown that some of these lesions develop into invasive squamous cell carcinoma (SCC), although others regress. Depending on the population studied pre-existing leucoplakia, the most common oral premalignant condition, is associated with 16-32% of oral cancers (MacDonald, 1975) . Erythroplakia is much rarer than leucoplakia but shows a much higher risk of malignant transformation. The clinical appearance of these lesions and recognised risk factors for oral cancer, which include heavy smoking and high alcohol consumption, are poorly predictive for risk of tumour development and therefore the lesions that will ultimately become neoplastic cannot readily be identified.
At (Fearon and Vogelstein, 1990) . Epidemiological, molecular and statistical studies have suggested that between six and ten genetic events are required for head and neck cancers (Harris, 1991; Renan 1993) . Genetic abnormalities affecting tumour-suppressor genes including allele loss at 9p2l-22 (van der Reit et al., 1994) and TP53 mutations (Boyle et al., 1993) Table I ).
The normal and dysplastic samples was performed using two rounds of PCR analysis as previously described (Sundaresan et al., 1992) . Amplification was performed in a volume of 50 pl containing 5 ,sl of DNA solution or 500 ng of genomic DNA. An aliquot of 15 jsl of the product was digested with 10 units of the appropriate restriction enzyme. The digests were fractionated on 4% agarose gels, stained with ethidium bromide and photographed. Allele (i) is the undigested amplification product, allele (ii) is composed of digested fragments.
PCR primers for 14 polymorphic microsatellite markers (see Table I ) were obtained from Research Genetics, Huntsville, USA or synthesised locally. One of the primers was end-labelled with [y-32P]ATP and PCR products generated from standard reactions. Products were separated by gel electrophoresis in denaturing 8% polyacrylamide-8M urea and autoradiographed overnight. Labelled M 13mp8 was included as a sequencing ladder to facailitate sizing of the alleles. The map positions of the markers (see Table II ) are given as indicated by the sigma mapping programme using data from the Genome Data Base, The Johns Hopkins University (Naylor et al., 1994 Figure 1 ) with representative cases (Figure 2) . Allelic deletions or imbalance generally involved single loci, although some samples showed deletion with adjacent probes. The most frequent region of chromosomal loss was between 3p2l.3-22.1 (overall LOH 33%), with a separate area of deletion at 3pl2.1-13 (overall LOH 14.8%). LOH at 3p24-pter, which has been previously reported for head and 811 .ieck and oral cancer (Masetro et al., 1993; Naggar et al., 1993; Partridge et al., 1994; Wu et al., 1994) LOH or allele imbalance at specific chromosomal regions was not associated with the grade of the dysplasia. These abnormalities were detected in mild (five) moderate (two) and severe dysplasia (two) in the absence of SCC and also in mild (two), moderate (three) and severe (two) cases with an invasive component. Normal oral mucosa was analysed for 16 cases with allele imbalance (7, 9, (15) (16) (17) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) ) and retained all alleles tested. During the period of study 11 patients developed new dysplastic lesions at the same site (see Table I ), seven of these cases (2, 7, 13, (15) (16) (17) 28) showed LOH or allelic imbalance at the regions identified in the original biopsy.
Two cases (13 and 17) subsequently developed SCC at the site of the original dysplastic lesion. Both precancers showed LOH or allelic imbalance at 3p2l.3-22.1 and 3pl2.1-13 in the original biopsy, case 13 showed an additional deletion at TP53 in the paired tumour although D3S659 was retained. Nine of the SCCs that developed adjacent to the dysplastic lesions examined were also available for study (cases 22-30) . All tumours showed LOH or allele imbalance at TP53, DCC or the three regions identified at 3p, 3p24-pter, 3p2l.3-22.1 and 3pl2.1-13 (Figure 1) . Loss of several adjacent loci was frequently detected in the SCC that developed (24, 25, 27, 28) . One (five cases), two (three cases) or three (two cases) further regions of deletion were detected when the tumours were compared to the paired dysplastic lesions (Figure 1) . Two cases showed allele loss at D3S659 (3pl3, case 13) and DCC (case 24, see Figure 2 ) in the dysplasia but not in the tumour. Cases 13 and 24 contained >90% malignant cells suggesting that this finding may be a reflection of 'field change' within the oral mucosa. Table I . ai and aii represent the polymorphic alleles, size markers (M)l kb ladder.
Discussion
At present, assessment of the likely behaviour of precancerous lesions relies on examination of sections stained with haematoxylin and eosin. There is general agreement that the degree of atypia and other structural alterations can be classified as mild, moderate or severe and this is normally taken to indicate low, medium or high risk of progression to malignancy (Maerjer and Burkardt, 1976) . However this type of analysis is likely to be unreliable as a result of the subjectivity inherent in this kind of assessment and the different histological criteria used to define dysplasia in different centres. The carcinogenic process involves progressive accumulation of genetic abnormalities (Fearon and Vogelstein, 1990) and assessment of the number of 'hits' in oral precancer by regular molecular profiling from biopsy tissue might supplement histological assessment to help identify lesions which may recur or progress to malignancy. This report is the first to describe allelic loss or imbalance at TP53, DCC and regions at 3p in potentially malignant lesions but not in histologically normal oral mucosa. These genetic abnormalities were detected in mild, moderate and severe dysplasia, which suggests that tumour-suppressor genes may be inactivated at an early stage in the carcinogenic process. At least two regions of deletion at 3p were identified at 3p21.3-22.1 and 3pl2.1-13, areas that have previously been suggested to harbour potential tumour-suppressor genes for head and neck and oral cancer (Masetro et al., 1993; El-Naggar et al., 1993; Partridge et al., 1994; Wu et al., 1994) . LOH at 3p24-pter, was also seen in one case but might be due to random events. The majority of cases of LOH at DCC occurred in dysplastic lesions adjacent to frank SCC, suggesting that loss at this locus may be a later event.
Preliminary studies have also shown that deletion of DCC is a common event in oral cancer (data not shown).
In this study it was revealed that 13 of 16 patients with allelic imbalance at the chromosomal regions studied were smokers, suggesting that these areas may be some of the sites of genetic damage in this group of patients. This reinforces the view that individuals with potentially malignant oral lesions should be encouraged to stop smoking.
The same allele was lost in the dysplastic oral epithelium and five of seven paired tumours, favouring a monoclonal origin for most samples examined. Two cases showed different deletions in the dysplastic and malignant lesion suggesting a polyclonal process and revealing a molecular basis for 'field cancerisation' within the oral cavity (Slaughter et al., 1953) . This finding contrasts with a study of tumours of the larynx and hypopharynx (Nees et al., 1993) showing different TP53 mutations in all cases of tumour and tumourdistant mucosa examined, suggesting a multifocal polyclonal process within the upper aerodigestive tract.
LOH or allele imbalance at the regions studied occurred in 7 of 11 (64%) dysplastic lesions that recurred within 3 years. Deletion of loci at 3p2l.3-22.1, 3pl2.1-13 and TP53 was most frequent in these samples and may be related to altered cell proliferation within the epithelia. The number of allelic deletions or 'hits' was higher in the tumours adjacent to the dysplastic lesions and in the tumours that subsequently developed. As these specific deletions can be present in potentially malignant lesions and increase in number when SCC develops they may serve as a marker to identify lesions that may recur or progress to cancer. Long-term study of sequential biopsies of dysplastic and tumour samples obtained from a large series of patients is in progress to determine whether the frequency of allele loss in dysplastic lesions can predict the likely behaviour of these lesions. If an accumulation of these genetic abnormalities is shown to increase risk of tumour development this would help identify individuals who may benefit from regular oral screening examination and early intervention. 
